There are 2789 resources available
1868P - Real-world safety of the 6-weekly pembrolizumab regimen in cancer patients treated in South East London
Presenter: Matthaios Kapiris
Session: ePoster Display
1869TiP - A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)
Presenter: Funda Meric-Bernstam
Session: ePoster Display
1870TiP - Tazemetostat in combination with a PARP Inhibitor or checkpoint inhibitor in patients (Pts) with solid tumors
Presenter: Charles Rudin
Session: ePoster Display
1814P - Molecular profile and clinical data of patients with lung cancer harboring germline TP53 R337H mutation
Presenter: Carlos Diego Lopes
Session: ePoster Display
1815P - Prognostic value of conventional type 1 dendritic cells in breast cancer patients
Presenter: Elisa Gobbini
Session: ePoster Display
1816P - CHEK2 gene somatic loss in breast tumors from carriers of germline CHEK2 mutations
Presenter: Aglaya Iyevleva
Session: ePoster Display
1817P - In silico identification of a BRCA1/miR-29/DNMT3A-3B axes involved in estrogen receptor expression of BRCA1-associated breast cancers
Presenter: Manuela Santarosa
Session: ePoster Display
1818P - Body mass index (BMI) is not a cancer risk factor for BRCA1/2 carriers: A systematic review and meta-analysis of case-control studies
Presenter: Valerio Gristina
Session: ePoster Display
1819P - Markers of breast cancer molecular types in metastasis-associated CTC subsets
Presenter: Olga Savelieva
Session: ePoster Display
1820P - Hybrid circulating tumor cells in breast cancer
Presenter: Sergey Vtorushin
Session: ePoster Display